Clinical Trials Browser

Phase 2/3 × Biliary Tract Neoplasms × anlotinib × Clear all

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase 2/3 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms